In conversation with... Edouard Louis

from Listen to The Lancet Gastroenterology & Hepatology · host The Lancet

Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease.

Episode metadata supplied by the publisher feed · Published Feb 9, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... Edouard Louis

0:00 21:30

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Gastroenterology & Hepatology?

This episode is 21 minutes long.

When was this Listen to The Lancet Gastroenterology & Hepatology episode published?

This episode was published on February 9, 2023.

Can I download this Listen to The Lancet Gastroenterology & Hepatology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!